|
000
| 01888nam 2200313zi 4500 |
|---|
| 001 | 9.871535 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107163421 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 190412e20190402onc #o f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aYN5-176/2019E-PDF |
|---|
| 245 | 04|aThe impact of the Canada-United States-Mexico Agreement on prescription drug expenditures in Canada. |
|---|
| 264 | 1|aOttawa, Canada : |bOffice of the Parliamentary Budget Officer = Bureau du directeur parlementaire du budget, |c2 April 2019. |
|---|
| 300 | |a1 online resource (37 pages). |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Incidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada. |
|---|
| 500 | |aCover title. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"The Canada-United States-Mexico Agreement (CUSMA) provides an extension to the term of protection for data resulting from drug trials. The extension applies to a category of pharmaceuticals known as innovative biologics. These are drugs with complex structures that have become increasingly popular. In recent years, pharmaceutical companies have been seeking extensions to the terms of data protection for such biologics to bolster the market exclusivity given by patents"--Executive summary, page 1. |
|---|
| 692 | 07|2gccst|aTrade agreements |
|---|
| 692 | 07|2gccst|aDrugs |
|---|
| 710 | 1 |aCanada. |bOffice of the Parliamentary Budget Officer. |
|---|
| 775 | 08|tIncidence de l'Accord Canada-États-Unis-Mexique sur les dépenses en médicaments d'ordonnance au Canada.|w(CaOODSP)9.871626 |
|---|
| 856 | 40|qPDF|s870 KB|uhttps://publications.gc.ca/collections/collection_2019/dpb-pbo/YN5-176-2019-eng.pdf |
|---|